hydroxychloroquine has been researched along with Spondylarthropathies in 7 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Spondylarthropathies: Heterogeneous group of arthritic diseases sharing clinical and radiologic features. They are associated with the HLA-B27 ANTIGEN and some with a triggering infection. Most involve the axial joints in the SPINE, particularly the SACROILIAC JOINT, but can also involve asymmetric peripheral joints. Subsets include ANKYLOSING SPONDYLITIS; REACTIVE ARTHRITIS; PSORIATIC ARTHRITIS; and others.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To compare the efficacy and tolerability of single-agent sulfasalazine (SSZ) with combination therapies composed of SSZ and methotrexate (MTX) and SSZ, MTX and hydroxychloroquine (HCQ) in active spondyloarthropathy (SpA) patients with peripheral arthritis." | 5.11 | Combination therapies in spondyloarthropathies. ( Apraş, S; Calgüneri, M; Cobankara, V; Ertenli, I; Kiraz, S; Oztürk, MA, 2004) |
| "Rheumatic diseases were IA (60%) and CTD (40%)." | 1.56 | Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. ( Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M, 2020) |
| "Hydroxychloroquine is an agent used as a treatment but also considered as a prophylaxis for SARS-CoV-2 infection." | 1.56 | [SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease]. ( Bouchti, IE; Malek, SA, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 5 (71.43) | 2.80 |
| Authors | Studies |
|---|---|
| Sanchez-Piedra, C | 1 |
| Diaz-Torne, C | 1 |
| Manero, J | 1 |
| Pego-Reigosa, JM | 1 |
| Rúa-Figueroa, Í | 1 |
| Gonzalez-Gay, MA | 2 |
| Gomez-Reino, J | 1 |
| Alvaro-Gracia, JM | 2 |
| Nuño, L | 1 |
| Novella Navarro, M | 1 |
| Bonilla, G | 1 |
| Franco-Gómez, K | 1 |
| Aguado, P | 1 |
| Peiteado, D | 1 |
| Monjo, I | 1 |
| Tornero, C | 1 |
| Villalba, A | 1 |
| Miranda-Carus, ME | 1 |
| De Miguel, E | 1 |
| Bogas, P | 1 |
| Castilla-Plaza, A | 1 |
| Bernad-Pineda, M | 1 |
| García-Lorenzo, E | 1 |
| Rodríguez-Araya, T | 1 |
| Balsa, A | 1 |
| Pablos, JL | 1 |
| Galindo, M | 1 |
| Carmona, L | 1 |
| Lledó, A | 1 |
| Retuerto, M | 1 |
| Blanco, R | 1 |
| Martinez-Lopez, D | 1 |
| Castrejón, I | 1 |
| Fernández Fernández, D | 1 |
| Mera-Varela, A | 1 |
| Manrique-Arija, S | 1 |
| Mena Vázquez, N | 1 |
| Fernandez-Nebro, A | 1 |
| Murray, K | 1 |
| Quinn, S | 1 |
| Turk, M | 1 |
| O'Rourke, A | 1 |
| Molloy, E | 1 |
| O'Neill, L | 1 |
| Mongey, AB | 1 |
| Fearon, U | 1 |
| Veale, DJ | 1 |
| Malek, SA | 1 |
| Bouchti, IE | 1 |
| Hoppé, E | 1 |
| Masson, C | 1 |
| Audran, M | 1 |
| Drillon, M | 1 |
| Andreu, M | 1 |
| Saraux, A | 1 |
| Berthelot, JM | 1 |
| Maugars, Y | 1 |
| Hmamouchi, I | 1 |
| Morel, J | 1 |
| Calgüneri, M | 1 |
| Cobankara, V | 1 |
| Oztürk, MA | 1 |
| Ertenli, I | 1 |
| Kiraz, S | 1 |
| Apraş, S | 1 |
1 trial available for hydroxychloroquine and Spondylarthropathies
| Article | Year |
|---|---|
Combination therapies in spondyloarthropathies.
Topics: Adult; Arthritis; Drug Therapy, Combination; Female; Humans; Hydroxychloroquine; Male; Methotrexate; | 2004 |
6 other studies available for hydroxychloroquine and Spondylarthropathies
| Article | Year |
|---|---|
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, | 2020 |
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Az | 2020 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthrit | 2020 |
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude to Health; Biological Products; Chloroq | 2021 |
[SARS-CoV-2 infection in a patient treated by hydroxychloroquine and anti TNF α for Inflammatory Rheumatic Disease].
Topics: Antirheumatic Agents; Antiviral Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 | 2020 |
Whipple's disease diagnosed during biological treatment for joint disease.
Topics: Adalimumab; Adult; Aged; Anti-Bacterial Agents; Antibodies, Monoclonal; Antibodies, Monoclonal, Huma | 2010 |